Dailypharm Live Search Close

Nam In-soon's drug price recovery bill excludes rebates

By Lee, Jeong-Hwan | translator Choi HeeYoung

21.11.22 17:38:49

°¡³ª´Ù¶ó 0
It includes re-evaluation of original patent expiration and registration contracts. Kim Won is different from the bill

Upper limit of loss amount, 40% limit of difference


The "Return and refund of suspension of execution of drug prices" bill proposed by Rep. Nam In-soon of the Democratic Party of Korea varies in scope of application to benefits deletion, suspension of benefits, and drug price reduction due to revaluation of starting drugs. However, Rep. Nam In-soon's bill does not include the disposition of drug price reduction due to the detection of illegal rebates.

The two bills differ in that the previously proposed Democratic Party lawmaker Kim Won-yi's bill was subject to redemption and refund of only the original patent expiration drug price and the rebate detection drug price. As Rep. Nam recently proposed an additional revision to the National Health Insurance A

Lee, Jeong-Hwan(junghwanss@dailypharm.com)
If you want to see the full article, please JOIN US (click)